Rainbow Children’s Medicare Limited has announced its financial results for the quarter and financial year ended March 31, 2026. The Board of Directors has recommended a final dividend of ₹3.50 per share, subject to shareholder approval. Additionally, the company confirmed the re-appointment of its key leadership team, including the Managing Director and Whole Time Director, alongside the renewal of terms for independent board members for the next five years.
Financial Highlights and Dividend
The company has approved its standalone and consolidated financial results for the quarter and year ended March 31, 2026. Statutory auditors provided an unmodified opinion on these results. To reward shareholders, the Board has recommended a final dividend of ₹3.50 per equity share, representing a 35% payout on the face value of ₹10 per share. This dividend is pending approval at the 28th Annual General Meeting, which is scheduled for July 29, 2026, to be conducted via video conferencing.
Leadership Re-appointments
As part of its governance roadmap, the company has approved the re-appointment of its core leadership team for a fresh five-year term, effective from August 11, 2026, to August 10, 2031:
- Dr. Ramesh Kancharla: Re-appointed as Chairman and Managing Director.
- Dr. Dinesh Kumar Chirla: Re-appointed as Whole Time Director.
Furthermore, the Board has extended the tenures of independent directors Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati for second terms, ensuring continuity in corporate oversight and strategic direction.
Operational Updates
The company has set July 21, 2026, as the Record Date for determining eligibility for the final dividend and participation in the upcoming Annual General Meeting. Additionally, the Board has re-appointed M/s. Lavanya & Associates LLP as the Cost Auditors for the 2026-27 financial year to ensure continued operational transparency and regulatory compliance.
Source: BSE
